Severe Menopause Hot Flashes: What the Evidence Says About Treatment

A lot of women live with severe hot flashes for years before ever bringing them up at a doctor’s appointment — partly because they assume it’s just something to endure, partly because they don’t realize how much can actually be done. A few misconceptions about treatment come up again and again, and the evidence on them is worth knowing.

“Severe” is a clinical category, not just a complaint

Clinicians grade hot flashes as mild, moderate, or severe by how much they intrude on your life, for example whether the sweating forces you to stop what you are doing. Hot flashes that wake you up multiple times a night, soak through clothing, or hit more than several times a day are the kind that can fall into the moderate-to-severe range of vasomotor symptoms, which is more than “having a rough time.” That distinction matters because it changes which treatments are appropriate to discuss.

Hormone therapy’s risk profile is more nuanced than the headlines from 20 years ago

Much of the lingering fear around hormone therapy dates to the 2002 Women’s Health Initiative trial of combined estrogen plus progestin, which was stopped early because breast cancer risk exceeded its stopping boundary and which also found more strokes and lung blood clots than placebo.^[1] The 2022 position statement of The North American Menopause Society says that for women younger than 60 or within 10 years of menopause onset who have no contraindications, the benefit-risk ratio is favorable for treating bothersome hot flashes. The same statement says risks differ by type, dose, duration, route, timing, and progestogen use, and that treatment should be individualized and periodically reviewed.^[2]

Hormone therapy is not right for everyone. Risks include blood clots, stroke, and, with combined estrogen-plus-progestogen therapy, breast cancer,^[1] so a personal history of those conditions matters. A woman who still has a uterus needs a progestogen alongside estrogen. Tell your clinician right away about very heavy bleeding, bleeding between periods, or any bleeding after 12 months without a period.

Non-hormonal options exist, with their own trade-offs

For women who have contraindications to hormone therapy or prefer not to use it, there are prescription non-hormonal options worth asking about. They are medicines with their own side effects and monitoring: for example, fezolinetant (Veozah) carries an FDA boxed warning for liver injury, and its label calls for liver blood tests before treatment and at scheduled intervals during the first 9 months.^[3] Ask your clinician which option fits your health history.

Symptoms can last for years, and you do not have to wait to ask

Some women’s vasomotor symptoms do fade with time; others last for years. A common mistake is assuming you have to wait it out to find out which category you’re in — there’s little downside to raising it early and revisiting the plan as things change.

The bottom line

If hot flashes are disrupting your sleep, work, or daily life, that’s a reason to have a real conversation, not just a reason to buy a better fan. Talk with a clinician about your symptoms and your personal and family health history before starting or stopping any treatment.

References

1. Writing Group for the Women’s Health Initiative Investigators. “Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women’s Health Initiative Randomized Controlled Trial.” JAMA. 2002;288(3):321-333. DOI: 10.1001/jama.288.3.321. Finding: in 16,608 women aged 50-79 with a uterus, combined estrogen plus progestin versus placebo was stopped after a mean 5.2 years because invasive breast cancer risk exceeded the stopping boundary; hazard ratios were 1.26 for invasive breast cancer, 1.41 for stroke, 2.13 for pulmonary embolism and 1.29 for coronary heart disease. ↑︎
2. “The 2022 hormone therapy position statement of The North American Menopause Society.” Menopause, 2022;29(7):767-794. Finding used: for women younger than 60 or within 10 years of menopause onset without contraindications, the benefit-risk ratio for hormone therapy is favorable for treatment of bothersome vasomotor symptoms. DOI: 10.1097/GME.0000000000002028. ↑︎
3. VEOZAH (fezolinetant) tablets, prescribing information: Boxed Warning (hepatotoxicity) and section 5.1. U.S. Food and Drug Administration, drug label effective 2026-02-26, retrieved via openFDA drug label API 2026-10-14. https://api.fda.gov/drug/label.json?search=openfda.brand_name:veozah. Finding: boxed warning for hepatotoxicity; hepatic laboratory tests before initiation, monthly for the first 3 months, and at 6 and 9 months. ↑︎

Kurt Greiner

Kurt is a digital strategist and IT professional blending emerging technology with practical application to help businesses and individuals streamline their digital presence. His current work focuses on the intersection of intentional living and technological resilience, exploring how individuals can leverage modern tools to navigate the second half of life with purpose.